Medical and Scientific Advisory Board
Chair - Steven Gallinger, M.Sc., MD
Dr. Gallinger is a Hepatobiliary/pancreatic (HPB) surgical oncologist at Princess Margaret Cancer Centre at University Health Network. He was recently appointed the inaugural Joseph and Wolf Lebovic Chair in Hepato-Pancreatico-Biliary Surgery at University Health Network. He is a Professor of Surgery at the University of Toronto, Head of the HPB Surgical Oncology Program at UHN and Mount Sinai Hospital (MSH) and Chair of the Cancer Care Ontario HPB Community of Practice.
His research interests are primarily in the area of GI cancer genetics and he is co-Director of the Centre for Cancer Genetics at the Samuel Lunenfeld Research Institute, co-PI of the Zane Cohen Familial Gastrointestinal Cancer Registry at MSH and also PI of the Ontario Pancreas Cancer Study. He is a member of the NIH funded Pancreas Cancer Genetic Epidemiology consortium and was recently appointed as Lead of the Translational Research Initiative in pancreas cancer, termed PanCuRx.
Dr. Gallinger is also the Co-Director of the McCain Centre for Pancreatic Cancer at the Princess Margaret, a chair of the GI Cancer Program at PMH and was recently appointed Chair of the GI committee for National Cancer Institute of Canada [NCIC].
Honorary Chair - Malcolm J Moore, MD
Dr. Malcolm Moore is the President of BC Cancer Agency. He oversees a comprehensive Cancer Control Program including prevention, screening, diagnosis, treatment and supportive care for the five million citizens of British Columbia.
Dr. Moore is also a practicing medical oncologist, a researcher and clinical pharmacologist involved in drug development work for cancer therapy. He continues to have a clinical practice in gastrointestinal (GI) oncology in addition to his administrative duties. Prior to his appointment as President of BC Cancer Agency, Dr. Moore was Director of the Drug Development Program and Co-Director of the McCain Centre for Pancreatic Cancer at Princess Margaret Hospital in Toronto.
He is also the past President of the International Society of Gastrointestinal Oncology. Over the past two decades, Dr. Moore has been involved in the development of new cancer therapies, has been a principal investigator in a number of practice changing clinical studies, has authored over 250 peer-reviewed publications and has given more than 200 invited lectures worldwide.
Members - Representing Centres of Excellence across Canada
Dan Renouf, MD, MPH
Dr. Renouf is a medical oncologist at the British Columbia Cancer Agency, Vancouver Centre, Co-Director of Pancreas Cancer BC and an Assistant Professor at the University of British Columbia, Department of Medicine.
He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and British Columbia Cancer Agency.
He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University. His research interests include developmental therapeutics and molecular epidemiology within gastrointestinal cancers, with a focus on pancreatic cancer. Click here to read his journey.
David Schaeffer, MD
Dr. Schaeffer is an Assistant Professor in the Department of Pathology & Laboratory Medicine at The University of British Columbia and heads the Division of Anatomic Pathology at Vancouver General Hospital.
Dr. Schaeffer obtained his medical degree from the Johanna’s Guenzberg University of Mainz, Germany. After a Residency Program in Anatomical Pathology in Vancouver he completed his Gastrointestinal Pathology Fellowship at Mount Sinai Hospital.
Dr. Schaeffer is a co-Director of the Pancreas Centre BC and also heads the Gastrointestinal Biobank (GIBB) at Vancouver General Hospital. He has an active research program focusing predominately on translational research in colonic and pancreatic cancer.
Patricia Tang, MD
Dr. Tang is a Medical Oncologist at the Tom Baker Cancer Centre and Clinical Associate Professor in the Departments of Oncology and Medicine at the Cumming School of Medicine, University of Calgary. She graduated with distinction from the University of Alberta’s medical school, and completed a fellowship in gastrointestinal oncology and drug development at the Princess Margaret Hospital and the University of Toronto, Canada.
Dr. Tang was awarded the 2016 Ralph Meyer Phase III Program Young Investigator Award from the Canadian Clinical Trials group. Currently, she is a full member of the Arnie Charbonneau Cancer Institute and has won many teaching awards. Her academic interests include health services research and early phase clinical trials.
Jim Biagi, MD
Dr. Biagi is a medical oncologist and Deputy department head, department of oncology, Queens University and Kingston Regional Cancer Centre Institute, medical oncologist, Cancer Research Institute at Queen’s University and co-chair, Cancer Care Ontario Gastrointestinal Cancer Disease Site Group Cancer Centre of Southeastern Ontario, Kingston General Hospital.
He has found that a delay between surgery and chemotherapy can lead to a decrease in overall survival and disease-free survival for CRC patients. He is currently studying the benefit of chemotherapy to help prevent recurrence, for patients who have had surgery for pancreatic cancer.
George Zogopoulos, MD
Dr. Zogopoulos is an assistant professor of surgery at McGill University, a hepato-pancreato-biliary and abdominal organ transplant surgeon at the McGill University Health Centre, and a clinician-scientist at the Rosalind and Morris Goodman Cancer Research Centre and the Research Institute of the McGill University Health Centre.
He is a scholar of the Fonds de Recherche du Québec - Santé, with a translational research program in pancreatic cancer. Dr. Zogopoulos established and directs the Quebec Pancreas Cancer Study, a familial pancreatic cancer and peri-ampullary tumour research registry.
His research focuses on the genetics and molecular subtypes of pancreatic cancer and includes a clinical screening program for individuals at increased risk for pancreatic cancer.
Carman Giacomantonio, BSc., MD, MSc,
Professor, Faculty of Medicine, Department of Surgery, Dalhousie University
Dr. Giacomantonio has practiced as a Surgical Oncologist in the Department of Surgery at Dalhousie University since 1999. His clinical focus is in the treatment of peritoneal based malignancies, sarcoma and melanoma. As a Surgical Scientist, Dr. Giacomantonio leads a team of researchers and students at the Sir Charles Tupper Medical Building at Dalhousie University where his lab is focused primarily on cancer immunology. Diseases being studied include melanoma, breast cancer and pancreatic cancer. Dr. Giacomantonio’s research funding comes from his Dalhousie University Senior Clinical Scholar Award, The QEII Hospital Foundation, and The Dalhousie Medical Research Foundation.
Dr. Giacomantonio recently initiated the creation of the Atlantic Canada Pancreatic Cancer Tumor and Knowledge Bank to enable him and other pancreatic cancer researchers to develop a greater focus of research in the diagnosis and treatment of patients with pancreatic cancer.
Dr. Giacomantonio is passionate about cancer research and treatment. As former Chief Medical Director for Cancer Care Nova Scotia he is a respected leader and teacher. He has been awarded resident teacher of the year three times and as an Italian Canadian, was awarded the “Order of Merit of the Italian Republic – Cavaliere” ,in 2013 for his dedication to teaching, cancer research, and his contribution to the care of people with cancer in Nova Scotia.